Tyler Robinson trial

Showing 685 articles
Business

C4 Therapeutics: Can Its Protein-Degrading Tech Ignite a Biotech Rally?

Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.

Business

Argan, Inc. (AGX): The Quiet Powerhouse in Energy Infrastructure

Argan, Inc., a specialized engineering and construction firm, is drawing investor attention with its robust financial performance, zero-debt balance sheet, and strategic positioning in the evolving energy sector. Despite a premium valuation, its record backlog and cash-generating prowess present a compelling bull case.